SER-252 completes cohort one, advances to cohort two
SER-252, a novel therapy for advanced Parkinson’s, has completed cohort one in its phase I-B study and advanced to cohort two, with top-line data expected in early 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.